INCATE and Kineticos join forces in supporting AMR innovators
INCATE (the INCubator for Antibacterial Therapies in Europe) and Kineticos AMR Accelerator Fund I (KAMRA I), have announced the beginning of a new collaboration that aims to enhance the support for innovators in the fight against drug-resistant infections. The German Center for Infection Research (DZIF) is one of INCATE's founding members.
Antimicrobial resistance (AMR) refers to the capability of pathogens to resist the effectiveness of antibiotics from working against them. According to recent estimates from the scientific journal The Lancet, AMR alone was responsible for 1.27 million deaths in 2019. And studies show this number will keep on growing if we cannot come up with new solutions, as the current pipeline for antibiotics therapies is insufficient. Urgent action is needed to bolster the pipeline of new antimicrobial therapies.
“We are excited to see INCATE expanding its industry partners,” says Christoph Dehio, Director of the Swiss National Centre of Competence in Research (NCCR) – AntiResist and Board Member of INCATE. “Kineticos is a new investor in the AMR scene, which is excellent news and we are pleased that they chose to work with INCATE. We further welcome Dr Richard Snyder to the Selection Committee and look forward to collaborating with Dr Snyder on our shared objectives.”
“We are thrilled to work with the INCATE team and fellow Selection Committee Members in identifying and supporting the development of AMR technologies,” said Dr Snyder. “Kineticos is highly aligned with INCATE’s mission in supporting innovative companies addressing AMR, and the synergies both parties bring have the potential to accelerate the deployment of new antibiotic technologies. Our mission is to work towards a world without AMR.”
Dr Snyder, KAMRA I Venture Partner, brings extensive experience in life sciences research and entrepreneurship, having been involved as a scientific leader and advisor in the growth of several ground-breaking companies over his career.
Through this alliance with Kineticos, INCATE will enhance its capabilities in offering guidance and increases the available non-dilutive funding. It is also hoped that Kineticos will be able to actively help selected ventures build compelling business cases to attract further investors into the AMR field.
The INCATE support model has proven value for early-stage ventures and will continue to expand to new geographies and deepen ties with existing and new partners. INCATE and its partners look forward to supporting more innovators in their fight against drug-resistant bacterial infections.
About Kineticos
Kineticos Life Sciences (Kineticos) envisions a world without antimicrobial resistance, cancer and rare and neurodegenerative diseases. We are entrepreneurs helping entrepreneurs build companies to improve patient outcomes. Kineticos leverages our expertise, network, ecosystem, and capital to provide the most relevant insights and recommendations for our portfolio companies, building value every step of the way. Kineticos began investing in 2019 and through its investment vehicles has invested more than US$60M across 11 companies.
Contact for Kineticos: investorrelations@kineticos.com | www.kineticos.com | LinkedIn: @Kineticos
About INCATE
INCATE is a not-for-profit partnership which brings together translational and basic research, industry, experienced entrepreneurs and investors from across Europe and beyond. The German Center for Infection Research (DZIF), the research association InfectControl in Germany, the Swiss National Centre of Competence in Research (NCCR) – AntiResist, the University of Basel and the Leibniz-HKI are the academic founding members of INCATE with the University of Basel as virtual host. Together with the four industry partners Boehringer Ingelheim, Roche, Shionogi and MSD as well as other organisations, funders and investors, INCATE want to ensure that the pipeline of new antibiotics and diagnostics is filled and strengthened.
Source: INCATE press release
